Trial Profile

A Roll-over Study to Provide Continued Treatment With Rogaratinib in Participants Who Were Enrolled in Rogaratinib Studies

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rogaratinib (Primary)
Indications Breast cancer; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Urogenital cancer
Focus Adverse reactions
Sponsors Bayer

Most Recent Events

18 Mar 2021 Status changed from active, no longer recruiting to completed.
09 Feb 2021 Planned primary completion date changed from 31 May 2021 to 16 Feb 2021.
09 Feb 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com